PAVmed Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $71.0K | $3.0M | $2.5M | $377.0K | $500.0K |
| Cost of Revenue | $218.0K | $4.8M | $6.4M | $3.6M | $585.0K |
| Gross Profit | $-147.0K | $-1.8M | $-3.9M | $-3.2M | $-85.0K |
| Gross Margin | -207.0% | -61.3% | -156.8% | -858.6% | -17.0% |
| Operating Expenses | |||||
| Research & Development | $4.5M | $5.9M | $14.3M | $25.3M | $19.8M |
| SG&A Expense | $16.3M | $24.5M | $30.9M | $41.4M | $25.4M |
| Operating Income | $-21.8M | $-44.5M | $-68.8M | $-91.1M | $-54.4M |
| Operating Margin | -30,712.7% | -1,482.9% | -2,751.8% | -24,161.0% | -10,878.6% |
| Interest Expense | — | $45.0K | $589.0K | $1.3M | — |
| Pretax Income | $-2.5M | $28.4M | $-79.3M | $-103.2M | $-56.1M |
| Income Tax Expense | $0 | $0 | — | — | — |
| Net Income | $401.0K | $39.8M | $-64.2M | $-89.0M | $-50.3M |
| Net Margin | 564.8% | 1,326.4% | -2,567.0% | -23,602.9% | -10,069.4% |
| EPS (Basic) | $-5.63 | $99.15 | $-9.16 | $-15.03 | $-0.65 |
| EPS (Diluted) | $-5.63 | $14.90 | $-9.16 | $-15.03 | $-0.65 |
| Shares Outstanding (Basic) | 670.5K | 322.4K | 7.2M | 5.9M | 77.5M |
| Shares Outstanding (Diluted) | 670.5K | 2.2M | 7.2M | 5.9M | 77.5M |
| Dividends Per Share | — | — | — | — | — |